Lindus Health, an anti-CRO running radically faster, more reliable clinical trials for life science pioneers, has appointed Professor Robert S. Langer, renowned scientist, Institute Professor at Massachusetts Institute of Technology (MIT), and co-founder of Moderna, to its Advisory Board.
“Lindus Health’s approach to clinical trial execution and their associated technologies should be incredibly helpful to biotech and pharmaceutical companies and enable them to bring new therapies to market faster and more efficiently,” Dr. Langer said. “Their technologies and site capabilities, in addition to a full suite of trial management services, sets them apart from most other CROs today. I am enthusiastic to be joining their advisory board.”
Dr. Langer has received more than 220 major awards, has authored over 1,570 articles, and has more than 1,400 patents issued and pending globally. These patents have been licensed or sublicensed to over 400 companies spanning pharmaceuticals, chemicals, biotechnology, and medical devices. He is the most cited engineer in history (h-index 319 with more than 412,500 citations according to Google Scholar).
“We are incredibly humbled to welcome Dr. Langer to our advisory board,” said Michael Young, co-founder of Lindus Health. “As Lindus Health continues to work with dedicated sponsors to bring innovative and essential therapies to the hands of patients, his unparalleled expertise and visionary contributions will serve as an invaluable asset to our business strategy. We look forward to working with Dr. Langer to bring our innovative approach to running clinical trials to biotech and pharma companies across the industry.”